BMY Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

12.24B

-0.85%

1.675

+0.3%

10.47B

-6.51%

1.436

-20.22%

11.35B

-7.5%

1.589

+8.83%

Estimates Revision

The market is revising Upward the revenue expectations for Bristol-Myers Squibb Company (BMY) for FY2025, with the revenue forecasts being adjusted by 1.4% over the past three months. During the same period, the stock price has changed by 25.51%.

Revenue Estimates for FY2025

Revise Upward

+1.4%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.44%

In Past 3 Month

Stock Price

Go Up

+25.51%

In Past 3 Month

18 Analyst Rating

Wall Street analysts forecast BMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 52.67 USD with a low forecast of 36.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

11 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

36.00

Averages

52.67

High

68.00

Current: 0.000

Low

36.00

Averages

52.67

High

68.00

UBS

Neutral -> Buy

upgrade

$46 -> $65

2026-01-07

New

Reason

UBS

Price Target

$46 -> $65

2026-01-07

New

upgrade

Neutral -> Buy

Reason

UBS upgraded Bristol Myers to Buy from Neutral with a price target of $65, up from $46, after assuming coverage of the name. After several challenging years, biotech and pharma are emerging from a cyclical trough, supported by improving macro conditions, stronger fundamentals, increased FDA approvals, positive clinical data, and accelerating M&A, the analyst says in a research note. Investor confidence is expected to rise in 2026, setting the stage for sector outperformance, UBS adds.

Citi

Neutral

maintain

$45 -> $53

2026-01-07

New

Reason

Citi

Price Target

$45 -> $53

2026-01-07

New

maintain

Neutral

Reason

Citi raised the firm's price target on Bristol Myers to $53 from $45 and keeps a Neutral rating on the shares.

Goldman Sachs

Buy

maintain

$95 -> $99

2025-12-22

Reason

Goldman Sachs

Price Target

$95 -> $99

2025-12-22

maintain

Buy

Reason

Goldman Sachs raised the firm's price target on Cytokinetics (CYTK) to $99 from $95 and keeps a Buy rating on the shares. Cytokinetics received FDA approval for aficamten, now branded Myqorzo, to treat adults with symptomatic obstructive hypertrophic cardiomyopathy, improving functional capacity and symptoms, the analyst tells investors in a research note. The label appears marginally superior to Bristol Myers' (BMY) Camzyos and aligns with expectations for an incrementally differentiated REMS program, the firm says.

Goldman Sachs

Neutral -> Buy

upgrade

$55 -> $95

2025-12-18

Reason

Goldman Sachs

Price Target

$55 -> $95

2025-12-18

upgrade

Neutral -> Buy

Reason

As previously reported, Goldman Sachs upgraded Cytokinetics (CYTK) to Buy from Neutral with a price target of $95, up from $55. The firm views shares as poised to outperform the group given a series of near- to intermediate-term catalysts, arguing that the emerging data cuts from ODYSSEY-HCM increasingly support a view that Bristol Myers' (BMY) trial missed primarily due to drug exposure and study execution issues rather than mechanistic issues with cardiac myosin inhibition. The firm thinks that Cytokinetics has likely addressed these issues with ACACIA-HCM and should that study achieve statistical significance, as Goldman expects it will, it sees aficamten as potentially the only agent approved for two indications and likely to attain more favorable formulary positioning with label expansion.

Goldman Sachs

Neutral

maintain

$51 -> $57

2025-12-15

Reason

Goldman Sachs

Price Target

$51 -> $57

2025-12-15

maintain

Neutral

Reason

Goldman Sachs raised the firm's price target on Bristol Myers to $57 from $51 and keeps a Neutral rating on the shares.

BofA

Neutral -> Buy

upgrade

$52 -> $61

2025-12-15

Reason

BofA

Price Target

$52 -> $61

2025-12-15

upgrade

Neutral -> Buy

Reason

BofA upgraded Bristol Myers to Buy from Neutral with a price target of $61, up from $52.

Valuation Metrics

The current forward P/E ratio for Bristol-Myers Squibb Co (BMY.N) is 8.65, compared to its 5-year average forward P/E of 11.32. For a more detailed relative valuation and DCF analysis to assess Bristol-Myers Squibb Co 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

11.32

Current PE

8.65

Overvalued PE

24.92

Undervalued PE

-2.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

10.02

Current EV/EBITDA

8.90

Overvalued EV/EBITDA

14.26

Undervalued EV/EBITDA

5.79

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.74

Current PS

2.40

Overvalued PS

3.27

Undervalued PS

2.21

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 15753.1% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 15753.1% over the last month.

Sold

Bought

BMY News & Events

Events Timeline

No data

News

4.5

01-08NASDAQ.COM

US Stock Market Volatile, Nasdaq Hits 3.5-Week High

6.5

01-07Fool

Merck and Other Drugmakers Trade Below Average Valuations, Attracting Investor Interest

9.5

01-07NASDAQ.COM

Eli Lilly's GLP-1 Weight Loss Drug Drives P/E Ratio to 53

People Also Watch

Frequently Asked Questions

What is Bristol-Myers Squibb Co (BMY) stock price today?

The current price of BMY is 55.9 USD — it has decreased -1.45 % in the last trading day.

What is Bristol-Myers Squibb Co (BMY)'s business?

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

What is the price predicton of BMY Stock?

What is Bristol-Myers Squibb Co (BMY)'s revenue for the last quarter?

Bristol-Myers Squibb Co revenue for the last quarter amounts to 12.22B USD, increased 2.77 % YoY.

What is Bristol-Myers Squibb Co (BMY)'s earnings per share (EPS) for the last quarter?

Bristol-Myers Squibb Co. EPS for the last quarter amounts to 1.08 USD, increased 80.00 % YoY.

What changes have occurred in the market's expectations for Bristol-Myers Squibb Co (BMY)'s fundamentals?

How many employees does Bristol-Myers Squibb Co (BMY). have?

Bristol-Myers Squibb Co (BMY) has 34100 emplpoyees as of January 09 2026.

What is Bristol-Myers Squibb Co (BMY) market cap?

Today BMY has the market capitalization of 113.80B USD.